Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 250 microgram - tablet, uncoated - excipient ingredients: magnesium stearate; rice starch; lactose monohydrate; oxidised maize starch; hydrolysed maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 0.0625 microgram - tablet, uncoated - excipient ingredients: lactose monohydrate; rice starch; magnesium stearate; hydrolysed maize starch; povidone; indigo carmine; oxidised maize starch - congestive heart failure - sigmaxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. sigmaxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because sigmaxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - sigmaxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 10 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings  and  dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery peri

United States - English - NLM (National Library of Medicine)

clinical solutions wholesale, llc - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 10 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated ( see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - ? hypoxia of any cause. ? as diluent for gaseous and volatile anaesthetic agents.

United States - English - NLM (National Library of Medicine)

advagen pharma ltd - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

Australia - English - Department of Health (Therapeutic Goods Administration)

coregas pty ltd - nitrous oxide, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - indications: 1. general anaesthesia: when an inhalation anaesthetic is required, the administration is usually accompanied by simultaneous administration of a volatile agent such as halothane, ethrane, etc. 2. analgesia with oxygen: - relief from severe pain, usually in emergency situations, by inhalation with oxygen. - useful also in short-term procedures which inevitably involve pain, such as wound and burn dressing, wound debridement and suturing. administration with oxygen. - in dental work to provide short-term analgesia for tooth extraction and other brief procedures. administration with oxygen. 3. others: - occasionally as an insufflating agent in laparoscopy. - in cryosurgery as a refrigerant.

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - solution - 10 mg in 5 ml - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the concurrent use of nortriptyline hydrochloride or other tricyclic antidepressants with a monoamine oxidase (mao) inhibitor is contraindicated. hyperpyretic crises, severe convulsions, and fatalities have occurred when similar tricyclic antidepressants were used in such combinations. it is advisable to discontinue the mao inhibitor at least 2 weeks before treatment with nortriptyline hydrochloride is to be started. patients hypersensitive to nortriptyline hydrochloride should not be given the drug. cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period after myocardial infarction.

United States - English - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period